Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
2009 1
2014 1
2016 7
2017 6
2018 3
2020 1
2021 5
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
Meneses-Lorente G, Guerini E, Mercier F, Parrott N, Kowalski K, Chow-Maneval E, Buchheit V, Bergthold G, Fox E, Phipps A, Djebli N. Meneses-Lorente G, et al. Among authors: guerini e. Cancer Chemother Pharmacol. 2023 Mar;91(3):239-246. doi: 10.1007/s00280-023-04510-1. Epub 2023 Mar 8. Cancer Chemother Pharmacol. 2023. PMID: 36884068 Free PMC article.
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Morcos PN, Cleary Y, Sturm-Pellanda C, Guerini E, Abt M, Donzelli M, Vazvaei F, Balas B, Parrott N, Yu L. Morcos PN, et al. Among authors: guerini e. J Clin Pharmacol. 2018 Dec;58(12):1618-1628. doi: 10.1002/jcph.1286. Epub 2018 Jul 27. J Clin Pharmacol. 2018. PMID: 30052269 Free PMC article.
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Meneses-Lorente G, Fowler S, Guerini E, Kowalski K, Chow-Maneval E, Yu L, Mercier F, Ullah M, Umehara K, Brink A, Buchheit V, Zwanziger E, Phipps A, Djebli N. Meneses-Lorente G, et al. Among authors: guerini e. Invest New Drugs. 2022 Feb;40(1):68-80. doi: 10.1007/s10637-021-01156-9. Epub 2021 Aug 21. Invest New Drugs. 2022. PMID: 34417912 Free PMC article.
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Meneses-Lorente G, Bentley D, Guerini E, Kowalski K, Chow-Maneval E, Yu L, Brink A, Djebli N, Mercier F, Buchheit V, Phipps A. Meneses-Lorente G, et al. Among authors: guerini e. Invest New Drugs. 2021 Jun;39(3):803-811. doi: 10.1007/s10637-020-01047-5. Epub 2021 Jan 18. Invest New Drugs. 2021. PMID: 33462752 Free PMC article. Clinical Trial.
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Hsu JC, Jaminion F, Guerini E, Balas B, Bordogna W, Morcos PN, Frey N. Hsu JC, et al. Among authors: guerini e. CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1357-1370. doi: 10.1002/psp4.12702. Epub 2021 Sep 21. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34547184 Free PMC article.
Population Pharmacokinetic and Exposure-dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients.
Cosson V, Schaedeli-Stark F, Arab-Alameddine M, Chavanne C, Guerini E, Derks M, Mallalieu NL. Cosson V, et al. Among authors: guerini e. Clin Transl Sci. 2018 Sep;11(5):523-531. doi: 10.1111/cts.12566. Epub 2018 Jun 27. Clin Transl Sci. 2018. PMID: 29877614 Free PMC article. Clinical Trial.
23 results